Skip to main content
English
Español
Company
Overview & History
Team
Join Oryzon
Epigenetics
Histone Code Hypothesis
Modulator Enzymes
LSD1 & Disease
Technology Platforms
Scientific Publications by Oryzon
Therapeutic Programs
Strategy
LSD1 & Cancer
LSD1 & CNS
Oryzon's Pipeline
Collaborative Research
Collaborative Projects
For Patient
Patient Information
Shareholders and Investors
Investor Information and News
Share Information
Events & Presentations
Financial Information & Downloads
Analyst Coverage
Corporate Governance
Corporate Social Responsibility
News & Press Releases
Contact
General Contact
Investor Contact
Email Alerts
News
Archive
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
News & Press Releases
29 May 2018
ORYZON receives approval in the United Kingdom to start ETHERAL: a Phase IIa clinical trial in Alzheimer’s Disease with ORY-2001
14 May 2018
ORYZON announces First Patients In ETHERAL: a Phase IIa clinical trial in Alzheimer’s Disease with ORY-2001
9 May 2018
ORYZON Reports Financial Results and Corporate Update for the 1st Quarter 2018
8 May 2018
ORYZON receives approval in France to start ETHERAL: a Phase IIa clinical trial in Alzheimer’s Disease with ORY-2001
3 May 2018
ORYZON covered for the first time by a US investment bank: ROTH Capital Partners
27 April 2018
Oryzon to present at upcoming international conferences
9 April 2018
Oryzon to present at upcoming international conferences
4 April 2018
ORYZON receives approval to start ETHERAL: a Phase IIa clinical trial in Alzheimer’s Disease with ORY-2001
5 March 2018
ORYZON Announces Publication of Paper in Cancer Cell establishing the relevance of ORY-1001 as an antileukemic differentiating drug
21 February 2018
Oryzon to present at upcoming international conferences
Pages
« first
‹ previous
…
2
3
4
5
6
7
8
9
10
…
next ›
last »